McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
What does it do?
McKesson is essentially the Amazon of medicine — it buys drugs in massive bulk from pharmaceutical manufacturers and delivers them to pharmacies, hospitals, clinics, and care homes across the US and beyond. When your local CVS or Walgreens needs to restock its shelves with everything from blood pressure pills to cancer treatments, there's a good chance McKesson is the company that shipped it. They also run software that helps pharmacies manage prescriptions more efficiently. Think of them as the invisible plumbing behind the US healthcare system.
McKesson moves over $400 billion worth of product a year, making it one of the largest companies in America by revenue — bigger than most household names you'd recognise. Drug distribution is a slow-moving but deeply essential industry, and McKesson controls roughly a third of the US market alongside just two other major competitors. With an ageing population driving more prescription drug demand every year, the underlying tailwind for this business is structural and hard to reverse.
How does it make money?
McKesson makes money primarily by buying drugs at wholesale prices and selling them to customers at a small markup — their gross profit looks tiny relative to their enormous revenue because the margins in distribution are razor-thin by design. On $403 billion in revenue last year (up from $359 billion the prior year), they earned about $4.8 billion in net profit, which is actually healthy given the business model. Additional revenue comes from their Prescription Technology Solutions segment, which sells software tools to pharmacies, and their oncology network, which connects cancer specialists and handles speciality drug distribution — a faster-growing and higher-margin part of the business.
Why do investors care?
The growth story at McKesson hinges on two things: the rapid expansion of speciality and cancer drugs, and the ageing of America. Speciality drugs — complex, expensive treatments for conditions like cancer or autoimmune disease — are the fastest-growing part of the pharmaceutical market, and McKesson is already one of the leading distributors in that space. Their oncology segment, which includes a network of independent cancer clinics, gives them a foothold in a market that's expected to grow significantly as new cancer therapies come to market. For the thesis to work, McKesson needs to keep winning distribution contracts, grow its oncology footprint, and benefit from continued drug price inflation boosting the dollar value of what it ships.
Deep Dive
MemberA full investor briefing on McKesson Corporation — history, leadership, risks, and outlook.